Daksha P Mehta, MD Internal Medicine - Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 584 Westport Rd, Ste 101, Elizabethtown, KY 42701 Phone: 270-769-2535 Fax: 270-769-9020 |
Dr. Saleem Sajid, M.D. Internal Medicine - Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 914 N Dixie Ave Ste 206, Elizabethtown, KY 42701 Phone: 270-737-7021 Fax: 270-982-3590 |
Dr. Mohammed Adnan Siddiqui, M.D. Internal Medicine - Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 1107 Woodland Dr, Suite 105, Elizabethtown, KY 42701 Phone: 270-769-6665 Fax: 270-769-0322 |
News Archive
A team of scientists from the United States has recently compared the immune response elicited by natural severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19) vaccination. Their findings reveal that, unlike vaccination, natural SARS-CoV-2 infection is associated with a robust interferon response together with an induction of cytotoxic gene expression in peripheral blood lymphocytes. The study is currently available on the medRxiv* preprint server.
Oncolytics Biotech Inc. today announced that it has received a No Objection Letter from Health Canada to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers.
A report published on Wednesday by the Center for Strategic & International Studies (CSIS) - titled "U.S. Global Health Policy in Palestinian Hands?" and written by J. Stephen Morrison, senior vice president and director of the Global Health Policy Center at CSIS, and Haim Malka, senior fellow and deputy director of the CSIS Middle East Program - examines the relationship between Palestine's bid for statehood and potential membership in U.N. bodies - including the WHO - and U.S. global health policy, according to the report summary.
CrystalGenomics, Inc. and CG Pharmaceuticals, Inc., a biopharmaceutical company with 3 clinical stage candidates, has announced that the first patient has been enrolled for a Phase 2b clinical study of CG100649, CrystalGenomics' clinical stage novel NSAID candidate, in patients with knee or hip osteoarthritis.
› Verified 5 days ago